198 related articles for article (PubMed ID: 23801633)
1. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
Strati P; Keating MJ; Wierda WG; Badoux XC; Calin S; Reuben JM; O'Brien S; Kornblau SM; Kantarjian HM; Gao H; Ferrajoli A
Blood; 2013 Aug; 122(5):734-7. PubMed ID: 23801633
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Ferrajoli A; Lee BN; Schlette EJ; O'Brien SM; Gao H; Wen S; Wierda WG; Estrov Z; Faderl S; Cohen EN; Li C; Reuben JM; Keating MJ
Blood; 2008 Jun; 111(11):5291-7. PubMed ID: 18334676
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wen S; Lee BN; Sivina M; Reuben J; Wierda WG; O'Brien SM; Faderl S; Kornblau SM; Burger JA; Ferrajoli A
Blood; 2011 Sep; 118(13):3489-98. PubMed ID: 21725050
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
[TBL] [Abstract][Full Text] [Related]
6. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Lee BN; Gao H; Cohen EN; Badoux X; Wierda WG; Estrov Z; Faderl SH; Keating MJ; Ferrajoli A; Reuben JM
Cancer; 2011 Sep; 117(17):3999-4008. PubMed ID: 21858802
[TBL] [Abstract][Full Text] [Related]
7. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Spina F; Rezzonico F; Farina L; Corradini P
Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan A; Kalakonda N; Pettitt AR
Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X; Wierda WG; Rezvani K; Reuben JM; Burger JA; Keating MJ; Ferrajoli A
Clin Cancer Res; 2016 May; 22(10):2359-67. PubMed ID: 26733610
[TBL] [Abstract][Full Text] [Related]
12. [Application of lenalidomide in chronic lymphocytic leukemia].
Lei W; Zhou KS; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner FJ; Zaborsky N; Neureiter D; Huemer M; Melchardt T; Egle A; Rebhandl S; Catakovic K; Hartmann TN; Greil R; Geisberger R
Haematologica; 2014 May; 99(5):67-9. PubMed ID: 24561794
[No Abstract] [Full Text] [Related]
14. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
[TBL] [Abstract][Full Text] [Related]
16. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A; Steurer M; Melchardt T; Weiss L; Gassner FJ; Zaborsky N; Geisberger R; Catakovic K; Hartmann TN; Pleyer L; Voskova D; Thaler J; Lang A; Girschikofsky M; Petzer A; Greil R
Ann Hematol; 2018 Oct; 97(10):1825-1839. PubMed ID: 29862437
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
[TBL] [Abstract][Full Text] [Related]
19. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]